The Mechanism of Action of Ethoxidol on Oxidative Stress Indices in Heart Failure and Hypotension

The aim of the investigation was to study the effect of 2-ethyl-6-methyl-3-hydroxypyridine malate (Ethoxidol) on the concentration of oxidative stress metabolites in patients with chronic heart failure (CHF) and hypertension.

Materials and Methods. 126 patients with FC I–III CHF have been examined. In addition to their individual therapy these patients received intravenous infusions of Ethoxidol. Blood content of 2,3-diphosphoglycerate (2,3-DPG), oxygen tension (рО₂), pH, concentration of total peroxides, lactate, and aldosterone were identified. 2,3-DPG levels (g/L erythrocytes) in whole blood samples were determined by an enzyme assay using the reagent kit (Rosh, Germany), values of рО₂, рСО₂, рН, lactate in the venous blood were measured using gas analyzer Stat Profil pHOx Ultra (Nova Biomedical, USA). Indices of oxidative stress, i.e. the concentration of plasma total peroxides, were investigated by ELISA using OxyStat kit (Biomedica, Austria). Peripheral venous blood samples were collected from all patients before and 6 days after the daily intravenous Ethoxidol infusion.

Results. In patients with FC I, II, III CHF, on day 7 after intravenous Ethoxidol infusion at a dose of 100 mg/day, statistically significant growth (p=0.0002) of PaO₂ level by 15.7, 17.4, and 22.8%, respectively, was noted. In patients with FC I, II, III CHF in the group receiving standard therapy, statistically significant (p=0.002) reduction of 2,3-DPG level by 2.7, 2.4, and 4.0%, respectively, was registered. On day 7 after the infusion of Ethoxidol at a dose of 100 mg/day, its decrease by 5.7, 10.5, and 26.2%, respectively (p<0.0001), was also observed.

Conclusion. The increased concentrations of active oxygen forms have been established to negatively affect various bodily functions and adversely influence the pathophysiology of numerous diseases. Application of antioxidants, including Ethoxidol presented by us in this article, may become a clue to the development of preventive measures for many serious diseases.

1. Martinucci S., Szabò I., Tombola F., Zoratti M. Ca2+-reversible inhibition of the mitochondrial megachannel by ubiquinone analogues. FEBS Lett 2000; 480(2–3): 89–94, https://doi.org/10.1016/s0014-5793(00)01911-6.
2. Choksi K.B., Boylston W.H., Rabek J.P., Widger W.R., Papaconstantinou J. Oxidatively damaged proteins of heart mitochondrial electron transport complexes. Biochim Biophys Acta 2004; 1688(2): 95–101, https://doi.org/10.1016/j.bbadis.2003.11.007.
3. Littarru G.P., Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007; Suppl: S168–S174, https://doi.org/10.1016/j.mito.2007.03.002.
4. Siciliano G., Volpi L., Piazza S., Ricci G., Mancuso M., Murri L. Functional diagnostics in mitochondrial diseases. Biosci Rep 2007; 27(1–3): 53–67, https://doi.org/10.1007/s10540-007-9037-0.
5. Fokina K.V., Yazykova M.Y., Danshina P.V., Schmalhausen E.V., Muronetz V.I. Participation of glyceraldehyde-3-phosphate dehydrogenase in the regulation of 2,3-diphosphoglycerate level in erythrocytes. Biochemistry (Mosc) 2000; 65(4): 463–468.
6. Drapkina O.M., Palatkina L.O. Markers of cytokine activation and oxidative stress in patients with chronic heart failure. Serdechnaya nedostatochnost’ 2013; 14(6): 341–346.
7. Romanov B.K. Regulation of myocardial lysosomal enzyme activity by calcium. Biomeditsinskaya khimiya 2005; 51(6): 634–642.
8. Kukes V.G. Itogi issledovaniya otechestvennogo preparata, antioksidanta II pokoleniya ehtoksidola [The results of a study of a domestic drug, an antioxidant of the second generation of ethoxidol]. Moscow: ANO “MAKFiF”; 2017.
9. Kukes V.G., Prokof’ev A.B., Checha O.A., Goroshko O.A., Smirnov V.V., Krasnykh L.M., Vasilenko G.F., Otdelenov V.A., Temnaja I.S., Mjasnikov D.G., Pshenichnikov V.G., Grigor’ev M.I. Method for activating P450CYP3A4 isoenzyme in patients with chronic cardiac failure. Patent RU 2554775. 2014.
10. Palatkina L.O., Korneeva L.O., Drapkina O.M. Oxidative stress, its role in the pathogenesis of chronic heart failure, and potential methods of correction. Kardiovaskulyarnaya terapiya i profilaktika 2012; 11(6): 91–94.
11. Goroshko O.A., Novikov K.N., Kukes V.G., Voeikov V.L., Arkhipov V.V., Buravleva E.V., Berdnikova N.G., Zhestovskaya A.S. Correction of oxidative stress in patients with chronic cerebral ischemia. Klinicheskaya meditsina 2016; 94(7): 549–553.
12. Sousa T., Oliveira S., Afonso J., Morato M., Patinha D., Fraga S., Carvalho F., Albino-Teixeira A. Role of H(2)O(2) in hypertension, renin-angiotensin system activation and renal medullary disfunction caused by angiotensin II. Br J Pharmacol 2012; 166(8): 2386–2401, https://doi.org/10.1111/j.1476-5381.2012.01957.x.
13. Münzel T., Camici G.G., Maack C., Bonetti N.R., Fuster V., Kovacic J.C. Impact of oxidative stress on the heart and vasculature: part 2 of a 3-part series. J Am Coll Cardiol 2017; 70(2): 212–229, https://doi.org/10.1016/j.jacc.2017.05.035.
14. Yamamoto S., Tsutsui H., Tagawa H., Saito K., Takahashi M., Tada H., Yamamoto M., Katoh M., Egashira K., Takeshita A. Role of myocyte nitric oxide in β-adrenergic hyporesponsiveness in heart failure. Circulation 1997; 95(5): 1111–1114, https://doi.org/10.1161/01.cir.95.5.1111.
15. Sack M.N., Fyhrquist F.Y., Saijonmaa O.J., Fuster V., Kovacic J.C. Basic biology of oxidative stress and the cardiovascular system: part 1 of a 3-part series. J Am Coll Cardiol 2017; 70(2): 196–211, https://doi.org/10.1016/j.jacc.2017.05.034.

Kukes V.G., Parfenova О.K., Romanov B.K., Prokofiev А.B., Parfenova E.V., Sidorov N.G., Gazdanova А.А., Pavlova L.I., Zozina V.I., Andreev А.D., Aleksandrova T.V., Chernova S.V., Ramenskaya G.V. The Mechanism of Action of Ethoxidol on Oxidative Stress Indices in Heart Failure and Hypotension. Sovremennye tehnologii v medicine 2020; 12(2): 67, https://doi.org/10.17691/stm2020.12.2.08